Standard BioTools, Treeline Biosciences to Merge in All-Stock Deal

MT Newswires Live06-08

Standard BioTools (LAB) and Treeline Biosciences said Monday that they have agreed to merge in an all-stock transaction that will create a combined biopharma company focused on oncology and other diseases.

After the deal closes, expected in H2 2026, the combined company is expected to operate as Treeline Biosciences and list on Nasdaq under the ticker "TRLN."

Pre-merger Treeline stockholders will own about 84% of the combined company, while pre-merger Standard BioTools stockholders will own about 16% and receive one contingent value right per share tied to certain legacy asset proceeds and earnout payments, the companies said.

The companies said the deal adds roughly $450 million in net cash from Standard BioTools, bringing combined cash resources to more than $900 million, which is expected to fund operations into 2029.

The transaction has been approved by both boards and Treeline shareholders but still requires approval from Standard BioTools shareholders and regulators, they added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641481147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641481147","market":"sh","top_or_hot":-1,"title":"Standard BioTools, Treeline Biosciences to Merge in All-Stock Deal","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LAB\">Standard BioTools</a> (LAB) and Treeline Biosciences said Monday that they have agreed to merge in an all-stock transaction that will create a combined biopharma company focused on oncology and other diseases.</p><p>After the deal closes, expected in H2 2026, the combined company is expected to operate as Treeline Biosciences and list on Nasdaq under the ticker \"TRLN.\"</p><p>Pre-merger Treeline stockholders will own about 84% of the combined company, while pre-merger Standard BioTools stockholders will own about 16% and receive one contingent value right per share tied to certain legacy asset proceeds and earnout payments, the companies said.</p><p>The companies said the deal adds roughly $450 million in net cash from Standard BioTools, bringing combined cash resources to more than $900 million, which is expected to fund operations into 2029.</p><p>The transaction has been approved by both boards and Treeline shareholders but still requires approval from Standard BioTools shareholders and regulators, they added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Standard BioTools, Treeline Biosciences to Merge in All-Stock Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStandard BioTools, Treeline Biosciences to Merge in All-Stock Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-08 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LAB\">Standard BioTools</a> (LAB) and Treeline Biosciences said Monday that they have agreed to merge in an all-stock transaction that will create a combined biopharma company focused on oncology and other diseases.</p><p>After the deal closes, expected in H2 2026, the combined company is expected to operate as Treeline Biosciences and list on Nasdaq under the ticker \"TRLN.\"</p><p>Pre-merger Treeline stockholders will own about 84% of the combined company, while pre-merger Standard BioTools stockholders will own about 16% and receive one contingent value right per share tied to certain legacy asset proceeds and earnout payments, the companies said.</p><p>The companies said the deal adds roughly $450 million in net cash from Standard BioTools, bringing combined cash resources to more than $900 million, which is expected to fund operations into 2029.</p><p>The transaction has been approved by both boards and Treeline shareholders but still requires approval from Standard BioTools shareholders and regulators, they added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641481147","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641481147","pubTimestamp":1780920398,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Standard BioTools  and Treeline Biosciences said Monday that they have agreed to merge in an all-stock transaction that will create a combined biopharma company focused on oncology and other diseases.After the deal closes, expected in H2 2026, the combined company is expected to operate as Treeline Biosciences and list on Nasdaq under the ticker \"TRLN.\"Pre-merger Treeline stockholders will own about 84% of the combined company, while pre-merger Standard BioTools stockholders will own about 16% and receive one contingent value right per share tied to certain legacy asset proceeds and earnout payments, the companies said.The companies said the deal adds roughly $450 million in net cash from Standard BioTools, bringing combined cash resources to more than $900 million, which is expected to fund operations into 2029.The transaction has been approved by both boards and Treeline shareholders but still requires approval from Standard BioTools shareholders and regulators, they added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","LAB":"Standard BioTools Inc.","SMP":"Standard Motor Products Inc","BK4124":"机动车零配件与设备"},"translate_title":"Standard BioTools与Treeline Biosciences将以全股票交易合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMP":1.5,"LAB":1},"content_text":"Standard BioTools (LAB) and Treeline Biosciences said Monday that they have agreed to merge in an all-stock transaction that will create a combined biopharma company focused on oncology and other diseases.After the deal closes, expected in H2 2026, the combined company is expected to operate as Treeline Biosciences and list on Nasdaq under the ticker \"TRLN.\"Pre-merger Treeline stockholders will own about 84% of the combined company, while pre-merger Standard BioTools stockholders will own about 16% and receive one contingent value right per share tied to certain legacy asset proceeds and earnout payments, the companies said.The companies said the deal adds roughly $450 million in net cash from Standard BioTools, bringing combined cash resources to more than $900 million, which is expected to fund operations into 2029.The transaction has been approved by both boards and Treeline shareholders but still requires approval from Standard BioTools shareholders and regulators, they added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641481147","isCrawlerRequest":true}